Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Omega Healthcare Investors Inc Issues FY 2013 FFO Guidance In Line With Analysts' Estimates
Omega Healthcare Investors Inc announced that it expects for FY 2013 Adjusted Funds From Operations (FFO) available to common stockholders to be between $2.45 and $2.50 per diluted share. In addition, it expects its 2013 Adjusted Funds Available For Distribution (FAD) available to common stockholders to be between $2.20 and $2.25 per diluted share. The Company's Adjusted FFO and Adjusted FAD guidance for 2013 includes approximately $200 million of new investments; however, it excludes the impact of gains and losses from the sale of assets, additional divestitures, certain revenue and expense items, interest refinancing expense, capital transactions and restricted stock amortization expense. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report FFO of $2.24 for fiscal 2013.
Latest Developments for Omega Healthcare Investors Inc
Latest Key Developments in Healthcare
- MediClin AG's Chief Executive Officer Resigns
- Fortis Healthcare Ltd Announces Allotment Of Equity Shares Under IPP
- AdCare Health Systems Inc Issues Q1 2013 Guidance Below Analysts' Estimates; Comments On Q1 2013 Charge Guidance
- Cordlife Group Ltd Announces Proposed Acquisition Of CS Cell Technologies Pte. Ltd, Cordlife Stem Cell Technology Limited And Certain Assets Of P.T. Cordlife Indonesia
- Share this
- Link this
- Digg this


Follow Reuters